Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
Novo Suffers Loss in Lawsuit Against Pharmacy’s Copycat Ozempic
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
FiercePharma2d
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Sydney Morning Herald12d
‘I’m a massive burger lover’: The restaurants, rooftops and dishes Jelena Dokic thinks are ace
Add articles to your saved list and come back to them anytime. Former world number four tennis player Jelena Dokic has written two best-selling books, travels the world as a guest speaker ...
Nasdaq14d
See Which Of The Latest 13F Filers Holds Novo-Nordisk
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...
bnnbloomberg14d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of ...
Insider Monkey15d
Jim Cramer on Novo Nordisk A/S (NVO): ‘They Don’t Have The Production Capability’
I’d be careful.” Novo Nordisk A/S (NYSE:NVO) is involved in researching, developing, producing, and distributing pharmaceutical products. Over the past year, NVO stock is down more than 20% ...
Investors Chronicle16d
A pharma stock emerging from Novo Nordisk's shadow
Pharmaceutical companies such as Denmark's Lundbeck (DK ... sit alongside a massive valuation discount to its Danish neighbour Novo Nordisk (DK:NOVO.B). The runaway valuations for Novo and Eli Lilly ...